{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:04Z","timestamp":1787010184551,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Cardiac MRI (CMR) and PET aid in early diagnosis and follow-up of cardiac sarcoidosis.\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) PET\/computed tomography (CT) is a major criterion in diagnosing cardiac sarcoidosis disease activity and therapy response; however, requires stringent dietary modifications for suppressing myocardial uptake.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTANOC, targeting somatostatin receptors in sarcoid granulomas, maybe an alternative, showing minimal physiological myocardial uptake and not needing dietary modifications to suppress myocardial radiotracer activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      This prospective study enrolled 23 patients, either biopsy-proven pulmonary sarcoidosis with suspected cardiac involvement or primary cardiac abnormalities with clinical and histopathological diagnosis from a systemic site. Patients underwent CMR,\n                      <jats:sup>13<\/jats:sup>\n                      N-NH\n                      <jats:sub>3<\/jats:sub>\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT (post-low-carbohydrate, high-fat, high-protein diet), and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTANOC PET\/CT. Patient-wise and cardiac-segment-wise analysis was done using Cohen\u2019s\n                      <jats:italic toggle=\"yes\">\u03ba<\/jats:italic>\n                      to assess intermodality agreement among three modalities. Mean maximum standardized uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) and target-to-background blood pool ratio (TBR) were calculated for positive lesions on\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTANOC and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTANOC and CMR showed almost perfect segment-wise agreement [Cohen\u2019s\n                      <jats:italic toggle=\"yes\">\u03ba<\/jats:italic>\n                      : 0.88, 95% confidence interval (CI): 0.84\u20130.92,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004] and moderate patient-wise agreement (Cohen\u2019s\n                      <jats:italic toggle=\"yes\">\u03ba<\/jats:italic>\n                      : 0.51, 95% CI: 0.29\u20130.73,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003).\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and CMR showed almost perfect segment-wise agreement (Cohen\u2019s\n                      <jats:italic toggle=\"yes\">\u03ba<\/jats:italic>\n                      : 0.80, 95% CI: 0.76\u20130.84,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004) and substantial patient-wise agreement (Cohen\u2019s\n                      <jats:italic toggle=\"yes\">\u03ba<\/jats:italic>\n                      : 0.77, 95% CI: 0.58\u20130.96,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Mean lesion SUV\n                      <jats:sub>max<\/jats:sub>\n                      and TBR were similar for\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTANOC (6.6\u2005\u00b1\u20052.8 and 3.4\u2005\u00b1\u20051.4) and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG (9.0\u2005\u00b1\u20055.4 and 3.6\u2005\u00b1\u20051.2) (unpaired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.16 for SUV\n                      <jats:sub>max<\/jats:sub>\n                      ,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.68 for TBR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTANOC PET\/CT shows promise as a complementary imaging modality for cardiac sacoidosis, with diagnostic performance comparable in many aspects to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and CMR. Further prospective studies are warranted to validate its role.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002113","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:00:35Z","timestamp":1769677235000},"page":"541-551","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic performance of 68Ga-DOTANOC PET\/computed tomography in cardiac sarcoidosis: comparison with 18F-fluorodeoxyglucose PET\/computed tomography and cardiac magnetic resonance"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-0227","authenticated-orcid":false,"given":"Ritanshu","family":"Solanki","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-0361","authenticated-orcid":false,"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Bahl","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manphool","family":"Singhal","sequence":"additional","affiliation":[{"name":"Radiodiagnosis, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab and Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Debi","sequence":"additional","affiliation":[{"name":"Radiodiagnosis, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab and Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJM199704243361706","article-title":"Sarcoidosis.","volume":"336","author":"Newman","year":"1997","journal-title":"N Engl J Med"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12350-017-0978-9","article-title":"Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET\/CTin cardiac sarcoid detection and therapy monitoring.","volume":"24","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-8703(99)70115-8","article-title":"Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies.","volume":"138","author":"Uemura","year":"1999","journal-title":"Am Heart J"},{"key":"R4-20260401","first-page":"275","article-title":"Causes of death in patients with chronic sarcoidosis.","volume":"33","author":"Hu","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11886-019-1238-1","article-title":"Cardiac sarcoidosis.","volume":"21","author":"Mankad","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00259-007-0650-8","article-title":"Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.","volume":"35","author":"Ohira","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260401","first-page":"1989","article-title":"The usefulness of fasting 18F-FDG PET in the identification of cardiac sarcoidosis.","volume":"45","author":"Okumura","year":"2004","journal-title":"J Nucl Med"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12350-012-9668-9","article-title":"The role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis.","volume":"20","author":"Mc Ardle","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2362.1999.00498.x","article-title":"Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas: somatostatin receptor 2A in sarcoidosis.","volume":"29","author":"ten Bokum","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s12350-022-03135-w","article-title":"Semiquantitative evaluation of 68Ga-DOTANOC uptake in the normal myocardium: establishment of reference values.","volume":"30","author":"Kaushik","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12350-016-0522-3","article-title":"ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.","volume":"23","author":"Dilsizian","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-016-0207-6","article-title":"A dual tracer 68Ga-DOTANOC PET\/CT and 18F-FDG PET\/CTpilot study for detection of cardiac sarcoidosis.","volume":"6","author":"Gormsen","year":"2016","journal-title":"EJNMMI Res"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/MNM.0000000000000869","article-title":"Gallium-68 DOTA-NOC PET\/CT as an alternate predictor of disease activity in sarcoidosis.","volume":"39","author":"Sharma","year":"2018","journal-title":"Nucl Med Commun"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s12149-021-01641-4","article-title":"Comparison of 68Ga-DOTANOC PET\/CT with cardiac MRI in patients with clinical suspicion of cardiac sarcoidosis.","volume":"35","author":"Kaushik","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12350-019-01746-4","article-title":"Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol.","volume":"28","author":"Christopoulos","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"R16-20260401","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis.","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case-control study of sarcoidosis.","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20260401","first-page":"123","article-title":"The role of positron emission tomography-computed tomography\/magnetic resonance imaging in the management of sarcoidosis patients.","volume":"17","author":"Promteangtrong","year":"2014","journal-title":"Hell J Nucl Med"},{"key":"R19-20260401","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MCP.0b013e3283480d36","article-title":"Molecular imaging in sarcoidosis.","volume":"17","author":"Ma\u00f1\u00e1","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"R20-20260401","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2967\/jnumed.106.037499","article-title":"PET\/CT attenuation correction: breathing lessons.","volume":"48","author":"Bacharach","year":"2007","journal-title":"J Nucl Med"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data.","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4070\/kcj.2018.0246","article-title":"Recent advances in cardiac magnetic resonance imaging.","volume":"49","author":"Lee","year":"2019","journal-title":"Korean Circ J"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper.","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2004.11.069","article-title":"Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches.","volume":"45","author":"Abdel-Aty","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260401","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jcmg.2013.10.011","article-title":"CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis.","volume":"7","author":"Francone","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"R27-20260401","first-page":"246","article-title":"Diagnostic values of edema-sensitive T2-weighted imaging, TSE T1-weighted early contrast-enhanced imaging, late gadolinium enhancement, and the Lake Louise criteria in assessing acute myocarditis: a single-center cardiac magnetic resonance study.","volume":"48","author":"Alis","year":"2020","journal-title":"Turk Kardiyol Dern Ars"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jcmg.2011.11.022","article-title":"Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis.","volume":"5","author":"Lurz","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12350-020-02303-0","article-title":"Benefits of [68Ga]-DOTATATE PET-CT comparable to [18F]-FDG in patient with suspected cardiac sarcoidosis.","volume":"29","author":"Vachatimanont","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"R30-20260401","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semnuclmed.2020.03.005","article-title":"Imaging and quantification of cardiac sarcoidosis.","volume":"50","author":"Elwazir","year":"2020","journal-title":"Semin Nucl Med"},{"key":"R31-20260401","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00259-015-3181-8","article-title":"Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.","volume":"43","author":"Ohira","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R32-20260401","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2967\/jnumed.111.090662","article-title":"The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience.","volume":"53","author":"Youssef","year":"2012","journal-title":"J Nucl Med"},{"key":"R33-20260401","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis.","volume":"21","author":"Ahmadian","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"R34-20260401","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijcard.2015.05.075","article-title":"Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET\/CT for detection of cardiac sarcoidosis.","volume":"195","author":"Yokoyama","year":"2015","journal-title":"Int J Cardiol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:00:30Z","timestamp":1775030430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002113","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"2025-11-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}